ScienceDirect Publication: Urologic Oncology: Seminars and Original Investiga...
ScienceDirect RSS

The ubiquitin-proteasome system in prostate cancer and its transition to cast...
1 Jul 2010 at 1:43pm
Publication year: 2010
Source: Urologic Oncology: Seminars and Original Investigations, In Press, Corrected Proof, Available online 30 June 2010
Ioannis A., Voutsadakis , Christos N., Papandreou
Prostate cancer is the most common carcinoma in the male population. In its initial stage, the disease is androgen-dependent and responds therapeutically to androgen deprivation treatment but it usually progresses after a few years to an androgen-independent phase that is refractory to hormonal manipulations. The proteasome is a multi-unit protease system that regulates the abundance and function of a significant number of cell proteins, and its inhibition results in cancer cell growth inhibition and apoptosis and is already exploited in the clinic with the use of proteasome inhibitor bortezomib in multiple myeloma. In order to be recognized by the proteasome,...
Editorial Board
30 Jun 2010 at 1:41pm
Publication year: 2010
Source: Urologic Oncology: Seminars and Original Investigations, Volume 28, Issue 4, July-August 2010, Page i
[No author name available]
Contents
30 Jun 2010 at 1:41pm
Publication year: 2010
Source: Urologic Oncology: Seminars and Original Investigations, Volume 28, Issue 4, July-August 2010, Pages ii-iii
[No author name available]
Masthead
30 Jun 2010 at 1:41pm
Publication year: 2010
Source: Urologic Oncology: Seminars and Original Investigations, Volume 28, Issue 4, July-August 2010, Page iv
[No author name available]
The International Bladder Cancer Network
30 Jun 2010 at 1:41pm
Publication year: 2010
Source: Urologic Oncology: Seminars and Original Investigations, Volume 28, Issue 4, July-August 2010, Pages 375-376
H. Barton, Grossman , Colin P.N., Dinney , Bernd J., Schmitz-Dräger , Peter J., Goebell
p53 immunohistochemistry in bladder cancer?a new approach to an old question?
30 Jun 2010 at 1:41pm
Publication year: 2010
Source: Urologic Oncology: Seminars and Original Investigations, Volume 28, Issue 4, July-August 2010, Pages 377-388
Peter J., Goebell , Susan G., Groshen , Bernd J., Schmitz-Dräger
 Objective: For nearly 20 years, the putative prognostic value of P53 immunohistochemistry in bladder cancer has been controversially discussed, and key questions are still unanswered. The aim of this article was to elucidate the different findings using the new concept of a combined analysis of raw data from previously published material. Materials and methods: Twenty-six of 38 study centers approached contributed patient data sets according to the protocol requirements; 3,421 patients with bladder cancer from 25 centers are included in the further analysis. The entire study group (mean age: 66.5 years) comprised 2,697 males (78.8 %) and 719 females. For 2,298 patients (68%)...
Statistical consideration for clinical biomarker research in bladder cancer
30 Jun 2010 at 1:41pm
Publication year: 2010
Source: Urologic Oncology: Seminars and Original Investigations, Volume 28, Issue 4, July-August 2010, Pages 389-400
Shahrokh F., Shariat , Yair, Lotan , Andrew, Vickers , Pierre I., Karakiewicz , Bernd J., Schmitz-Dräger , ...
 Objective: To critically review and illustrate current methodological and statistical considerations for bladder cancer biomarker discovery and evaluation. Methods: Original, review, and methodological articles, and editorials were reviewed and summarized. Results: Biomarkers may be useful at multiple stages of bladder cancer management: early detection, diagnosis, staging, prognosis, and treatment; however, few novel biomarkers are currently used in clinical practice. The reasons for this disjunction are many and reflect the long and difficult pathway from candidate biomarker discovery to clinical assay, and the lack of coherent and comprehensive processes (pipelines) for biomarker development. Conceptually, the development of new biomarkers should be a process that is similar...
Molecular pathways of urothelial development and bladder tumorigenesis
30 Jun 2010 at 1:41pm
Publication year: 2010
Source: Urologic Oncology: Seminars and Original Investigations, Volume 28, Issue 4, July-August 2010, Pages 401-408
Mireia, Castillo-Martin , Josep, Domingo-Domenech , Orit, Karni-Schmidt , Tulio, Matos , Carlos, Cordon-Cardo
Bladder cancer is the fifth most common human malignancy and the second most frequently diagnosed genitourinary tumor after prostate cancer. The majority of malignant tumors arising in the urinary bladder are urothelial carcinomas. Clinically, superficial bladder tumors (stages Ta and Tis) account for 75% to 85% of neoplasms, while the remaining 15% to 25% are invasive (T1, T2?T4) or metastatic lesions at the time of initial presentation. Several studies have revealed that distinct genotypic and phenotypic patterns are associated with early vs. late stages of bladder cancer. Early superficial disease appears to segregate into 2 main pathways: (1) superficial papillary...
Bladder cancer or bladder cancers? Genetically distinct malignant conditions ...
30 Jun 2010 at 1:41pm
Publication year: 2010
Source: Urologic Oncology: Seminars and Original Investigations, Volume 28, Issue 4, July-August 2010, Pages 409-428
Peter J., Goebell , Margaret A., Knowles
Despite the fact that the current histopathologic classification for bladder cancer has led to improved concepts for the clinical management of the disease, key questions with regard to assessment of risk for recurrence and/or progression to invasive disease remain. In addition, response to specific therapies cannot be predicted accurately.Bladder tumors comprise a heterogeneous group with respect to both histopathology and clinical behavior. Thus, it is anticipated that a thorough knowledge and interpretation of the molecular alterations involved in tumor development and progression will lead to greater prognostic and predictive power. This may not only lead to better comprehension of the...
Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation...
30 Jun 2010 at 1:41pm
Publication year: 2010
Source: Urologic Oncology: Seminars and Original Investigations, Volume 28, Issue 4, July-August 2010, Pages 429-440
David J., McConkey , Sangkyou, Lee , Woonyoung, Choi , Mai, Tran , Tadeusz, Majewski , ...
Urothelial cancer has served as one of the most important sources of information about the mutational events that underlie the development of human solid malignancies. Although ?field effects? that affect the entire bladder mucosa appear to initiate disease, tumors develop along 2 distinct biological ?tracks? that present vastly different challenges for clinical management. Recent whole genome methodologies have facilitated even more rapid progress in the identification of the molecular mechanisms involved in bladder cancer initiation and progression. Specifically, whole organ mapping combined with high resolution, high throughput SNP analyses have identified a novel class of candidate tumor suppressors (?forerunner genes?)...
Considerations on implementing diagnostic markers into clinical decision maki...
30 Jun 2010 at 1:41pm
Publication year: 2010
Source: Urologic Oncology: Seminars and Original Investigations, Volume 28, Issue 4, July-August 2010, Pages 441-448
Yair, Lotan , Shahrokh F., Shariat , Bernd J., Schmitz-Dräger , Marta, Sanchez-Carbayo , Feliksas, Jankevicius , ...
Bladder cancer is a common disease that is often detected late and has a high rate of recurrence and progression. Cystoscopy is the main tool in detection and surveillance of bladder cancer but is invasive and can miss some cancers. Cytology is frequently utilized but suffers from a poor sensitivity. There are several commercially available urine-based tumor markers currently available but their use is not recommended by guideline panels. Markers such as the Urovysion FISH assay and the NMP22 BladderChek test are approved for surveillance and detection in patients with hematuria. The added benefit of these markers and other commercially...
New concepts of biobanks?strategic chance for uro-oncology
30 Jun 2010 at 1:41pm
Publication year: 2010
Source: Urologic Oncology: Seminars and Original Investigations, Volume 28, Issue 4, July-August 2010, Pages 449-457
Peter J., Goebell , Manuel M., Morente
Cancer, as well as other common diseases, is a complex condition that not only causes a major threat to human health, but also represents a huge burden to society in terms of healthcare cost and loss of economic productivity. Treatment improvements remain elusive, since the causes of cancer are due to a huge number of small and possibly additive effects arising from genetic susceptibility, lifestyle, and environmental conditions. Thus, progress in translational cancer research investigating these changes and their complex interaction is highly dependent on large series of cases (affected and unaffected individuals) including high quality samples and their associated...
Survey Section Editorial Board
30 Jun 2010 at 1:41pm
Publication year: 2010
Source: Urologic Oncology: Seminars and Original Investigations, Volume 28, Issue 4, July-August 2010, Page 458
[No author name available]
Commentary on Androgen receptor survival signaling is blocked by anti-{?}2-mi...
30 Jun 2010 at 1:41pm
Publication year: 2010
Source: Urologic Oncology: Seminars and Original Investigations, Volume 28, Issue 4, July-August 2010, Page 459
Kenneth S., Koeneman
Commentary on Role of DAB2IP in modulating epithelial-to-mesenchymal transiti...
30 Jun 2010 at 1:41pm
Publication year: 2010
Source: Urologic Oncology: Seminars and Original Investigations, Volume 28, Issue 4, July-August 2010, Pages 459-460
Kenneth S., Koeneman

Presented by MedRat®

MedRat BioArchives MedRat News Home e-Journals Home MedRat Feedback Download e-Journals Links Disclaimer / Copyrights